Protara Therapeutics Q1 net loss widens on higher expenses

Overview

• US biotechnology firm's Q1 net loss widened yr/yr on higher R&D and administrative expenses

• Company ended Q1 with $177 mln in cash, expected to fund operations into 2028

• Protara plans BLA submission for TARA-002 in lymphatic malformations in 2H 2027

Outlook

• Protara intends to submit a BLA for TARA-002 in LMs in 2H 2027

• Interim results from THRIVE-3 IV Choline Chloride trial expected in 2H 2026

Result Drivers

• R&D SPENDING - Higher research and development expenses driven by increased costs for the ADVANCED-2 trial and start-up costs for the ADVANCED-3 trial in NMIBC

• ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher personnel-related costs, including stock-based compensation

Company press release: ID:nGNX9gm3QJ

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Protara Therapeutics Inc is $25.00, about 385.4% above its May 12 closing price of $5.15

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.